| abstract |
The present invention provides 6-substituted-2,3,4,5-tetrahydro-1H-benzo[d]azepines of Formula (I) as selective 5-HT receptor agonists for the treatment of 5-HT associated disorders including obesity, obsessive/compulsive disorder, depression, and anxiety: where R is -C≡C-R, -CH=CRR , or -(C-C)alkyl-Ar optionally substituted on the alkyl moiety with 1 to 6 fluoro substituents and other substituents are as defined in the specification. |